Durvalumab After chemoRadioTherapy for NSCLC patients
– a phase II translational and biomarker study investigating PDL1 positive and negative patients
- EudraCT number: 2019-002537-11
- Clinicaltrials.gov: NCT04392505
| Background/study objectives |
| Study design |
| Collaborative partners |
| Update/publications |